Emerging clinical evidence suggests GLP-1 receptor agonists may reduce cravings for alcohol, nicotine, opioids, and other substances. We track every trial, every study, every data point — so you don't have to sort signal from noise.
GLP-1 receptors are expressed throughout the brain's reward circuitry — the same pathways hijacked by addiction. Researchers at the NIH, UNC, and institutions worldwide are now testing whether activating these receptors can quiet cravings across multiple substance categories.
The strongest evidence base. The 2025 JAMA Psychiatry RCT by Hendershot showed semaglutide significantly reduced heavy drinking days and total alcohol consumption versus placebo. Volkow's NIH cohort found 40% lower alcohol intoxication rates in GLP-1 users.
Strong Evidence — RCT Data Read the full analysis →UNC's active trial is studying semaglutide's effects on nicotine intake. Eli Lilly has announced dedicated nicotine cessation trials. Mechanism: GLP-1 receptors in the habenular circuits that govern avoidance behavior (Tuesta et al., Nature Neuroscience 2017).
Emerging — Active Trials Read the full analysis →Volkow's landmark cohort analysis found 78% reduced overdose risk in patients taking GLP-1s with concurrent opioid use disorder. A Pennsylvania multi-site trial is now enrolling. Grigson's rodent research demonstrates reduced opioid self-administration.
Strong Evidence — Cohort Data Read the full analysis →Wang et al. (2024, Molecular Psychiatry) reported a 44% reduction in cannabis use disorder diagnoses among GLP-1 users in a large retrospective cohort. Prospective trials are needed to confirm causation.
Emerging — Retrospective Data Read the full analysis →Anecdotal reports suggest reduced gambling urges and compulsive shopping behaviors. No clinical trials exist yet. The mechanism is plausible: GLP-1 modulates the same dopamine reward pathways implicated in behavioral addictions.
Early — Anecdotal Only Read the full analysis →GLP-1 receptors are expressed in the VTA, nucleus accumbens, amygdala, and prefrontal cortex — the core reward circuit. Semaglutide's superior brain penetration (vs. older GLP-1s like exenatide) may explain why it succeeds where first-generation drugs failed.
Strong — Neuroanatomy Read the full analysis →No GLP-1 medication is FDA-approved for treating addiction. Current research is promising but early. However, many people exploring GLP-1 treatment for weight loss report reduced cravings as an additional benefit. Here's how telehealth access works today.
GLP-1 medications are currently prescribed for weight management (BMI ≥ 27 with conditions, or ≥ 30). You'll complete an online health assessment.
A licensed clinician reviews your health profile and determines if GLP-1 treatment is appropriate. Approval isn't guaranteed.
If prescribed, medication ships to your door. Many patients report reduced cravings for alcohol, nicotine, and other substances as a secondary benefit.
These providers prescribe GLP-1 medications for weight management. Craving reduction for alcohol, nicotine, and other substances has been widely reported as an additional benefit by patients. All require a clinical evaluation.
We read the full-text studies, interview the researchers, and translate dense clinical data into clear analysis. New posts weekly as trials report and the science evolves.
A deep breakdown of the Hendershot JAMA Psychiatry RCT — methodology, effect sizes, what it means for the 29 million Americans with alcohol use disorder.
Coming SoonA living document covering the UNC, UT Houston, and Ottawa Phase 3 trials — updated as results drop.
Coming SoonThe NIH cohort analysis that made addiction researchers rethink everything about GLP-1 receptors in the reward pathway.
Coming SoonThis site reports on published clinical research involving GLP-1 receptor agonists and addiction. We do not claim that any telehealth provider treats addiction with GLP-1 medications — that is not an FDA-approved indication. The providers featured above prescribe GLP-1 medications for weight management. Many patients report reduced cravings for alcohol, nicotine, and other substances as a secondary benefit. Always consult a healthcare professional about your specific situation. If you are experiencing a substance use crisis, contact the SAMHSA National Helpline at 1-800-662-4357 (free, confidential, 24/7).